AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
You may also be interested in...
GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.
A pioneer in the field, can GSK’s investment in real world studies pay off?
Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.